North Texas Research Associates Trials

North Texas Research Associates	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Iftikhar, Faizan

NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting

12500

Europe, Canada, Japan, US, RoW

Lepodisiran Sodium, LY3819469, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

03/29

Park, Jean

TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Active, not recruiting

1250

Canada, US, RoW

Retatrutide, LY3437943, Semaglutide

Eli Lilly and Company

Diabetes Mellitus, Type 2

08/26

01/27

NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting

12500

Europe, Canada, Japan, US, RoW

Lepodisiran Sodium, LY3819469, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

03/29

QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed

928

Europe, Canada, Japan, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec

Eli Lilly and Company

Diabetes, Type 2 Diabetes

04/24

NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting

10000

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

02/29

QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed

692

Europe, Japan, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec

Eli Lilly and Company

Type 1 Diabetes, Diabetes

05/24

ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting

3000

Europe, Japan, US, RoW

Orforglipron, LY3502970, Placebo

Eli Lilly and Company

Obesity, Overweight, Overweight or Obesity

07/25

07/27

PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting

9541

Europe, Canada, Japan, US, RoW

Obicetrapib, Placebo

NewAmsterdam Pharma, Monash University

Atherosclerotic Cardiovascular Disease

11/26

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

NCT05343065: A Continuous Glucose Monitor Based Insulin Bolus Calculator (CGM-IBC) Study B

Completed

N/A

BlueStar 10

Welldoc

Diabetes Mellitus

12/22

STEP-1, NCT04101669: RESET System Pivotal Trial (Rev F)

Recruiting

N/A

264

RESET Liner, RESET Sleeve, Duodenal-jejunal Bypass Liner (DJBL), EndoBarrier, Sham

Morphic Medical Inc., Biostatistical Consulting, Inc.

Diabetes type2, Obesity

12/25

12/26

NCT05238142: In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes

Completed

N/A

574

MiniMed™ 780G Insulin Pump system

Medtronic Diabetes

Type 2 Diabetes Treated With Insulin

01/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Iftikhar, Faizan

NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting

12500

Europe, Canada, Japan, US, RoW

Lepodisiran Sodium, LY3819469, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

03/29

Park, Jean

TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Active, not recruiting

1250

Canada, US, RoW

Retatrutide, LY3437943, Semaglutide

Eli Lilly and Company

Diabetes Mellitus, Type 2

08/26

01/27

NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting

12500

Europe, Canada, Japan, US, RoW

Lepodisiran Sodium, LY3819469, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

03/29

QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed

928

Europe, Canada, Japan, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec

Eli Lilly and Company

Diabetes, Type 2 Diabetes

04/24

NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting

10000

Europe, Canada, US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)

02/29

QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Completed

692

Europe, Japan, US, RoW

Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec

Eli Lilly and Company

Type 1 Diabetes, Diabetes

05/24

ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting

3000

Europe, Japan, US, RoW

Orforglipron, LY3502970, Placebo

Eli Lilly and Company

Obesity, Overweight, Overweight or Obesity

07/25

07/27

PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting

9541

Europe, Canada, Japan, US, RoW

Obicetrapib, Placebo

NewAmsterdam Pharma, Monash University

Atherosclerotic Cardiovascular Disease

11/26

ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting

186

Canada, US

Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg

Zucara Therapeutics Inc.

Type 1 Diabetes Mellitus with Hypoglycemia

06/25

07/25

NCT05343065: A Continuous Glucose Monitor Based Insulin Bolus Calculator (CGM-IBC) Study B

Completed

N/A

BlueStar 10

Welldoc

Diabetes Mellitus

12/22

STEP-1, NCT04101669: RESET System Pivotal Trial (Rev F)

Recruiting

N/A

264

RESET Liner, RESET Sleeve, Duodenal-jejunal Bypass Liner (DJBL), EndoBarrier, Sham

Morphic Medical Inc., Biostatistical Consulting, Inc.

Diabetes type2, Obesity

12/25

12/26

NCT05238142: In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes

Completed

N/A

574

MiniMed™ 780G Insulin Pump system

Medtronic Diabetes

Type 2 Diabetes Treated With Insulin

01/25



	Diseases Companies Products Productz Mechanisms of Action Sites